Overview
Chemicals

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Kobayashi Pharmaceutical develops, manufactures, and markets a wide range of consumer healthcare and daily-use products, including OTC pharmaceuticals (Anmeltz, Ibon, Naishtol), oral care products (Tafudent, Breath Care), and household goods such as deodorants/air fresheners (Sawaday, Bluelet) and body care items (Kesimin, Kairo heat pads). The company's core strategy, 'Small Pond, Big Fish,' focuses on identifying niche consumer needs and creating uniquely positioned products under the philosophy of 'making what would be nice to have a reality.' Its business spans domestic and international segments, with operations across Asia, North America, Europe, and Australia through approximately 40 group companies.

Market Cap
¥530B
US$3.37B
EV
¥443B
US$2.82B
Stock¥7,128▼-0.31%
US$1 = ¥157.05 (2026-10-22)
LTM EV/EBITDA
24.3
x
LTM EV/EBIT
42.4
x
LTM PER
326.1
x
LTM PBR
2.5
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▲+12.3%pt
10012
Oct 23, 25 – Oct 23, 26StockTOPIX
1Dec 26, 25Oasis Management Company Ltd. changed stake (10.1%→13.06%)
2May 13, 26Oasis Management Company Ltd. changed stake (13.06%→13.37%)
MC → EV Bridge
530BUS$3.37BMarket Cap0.72BUS$4.60M+ Debt47.0BUS$299M− Cash41.0BUS$261M− Inv. Sec.0.01BUS$0.06M+ NCI443BUS$2.82BEV
AI Briefing
Kobayashi Pharma: niche-innovation OTC/household icon (Anmeltz, Bluelet, Breath Care) rebuilding trust post-2024 red yeast rice incident. FY25/12 revenue ¥166B flat, but OP margin compressed to 9.0% from 15.0% as quality/governance remediation costs bite. Activist Oasis holds 5.19% alongside founder family control (~20%+ combined); market cap ¥538B vs EV ¥450B reflects net cash cushion amid turnaround scrutiny.
Performance & Balance
Revenue 5Y (¥B)
155US$989M'21/12166US$1.06B'22/12173US$1.10B'23/12166US$1.05B'24/12166US$1.06B'25/12
EBITDA 5Y (¥B)
30.0US$191M'21/1231.0US$198M'22/1230.7US$196M'23/1231.5US$200M'24/1222.3US$142M'25/12
Net Income 5Y (¥B)
19.7US$126M'21/1220.0US$127M'22/1220.3US$130M'23/1210.1US$64.1M'24/123.66US$23.3M'25/12
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
124US$793M0.63US$4.01M'21/12125US$794M0.79US$5.04M'22/12104US$660M0.99US$6.28M'23/1275.5US$481M0.85US$5.39M'24/1294.2US$600M0.68US$4.32M'25/12
Shareholders
Top 10 hold 49.0%
1
Akihiro KOBAYASHI
12.46%
2
Kobayashi Foundation
8.07%
3
The Master Trust Bank of Japan, Ltd. (Trust Account)
7.21%
4
Oasis Japan Strategic Fund (Standing Proxy: Goldman Sachs Securities Co., Ltd.)
5.19%
5
Ikuko WATANABE
3.13%
6
Forum Co., Ltd.
2.79%
7
Oasis Japan Strategic Fund Y (Standing Proxy: Citibank, N.A., Tokyo Branch)
2.74%
8
Oasis Investment II Master Fund (Standing Proxy: Goldman Sachs Securities Co., Ltd.)
2.62%
9
Yukako IUE
2.51%
10
Ekō Co., Ltd.
2.29%
Management
10 officers
Yoshihito OTA
Chairman of the Board
Apr 1978 Joined Kyocera Corporation Jun 2003 Executive Officer, Kyocera Corporation Feb 2010 Deputy Trustee and Assistant to Chairman, Japan Airlines Co., Ltd. Jun 2010 Director and Managing Executive Officer, Kyocera Corporation Dec 2010 Senior Managing Executive Officer, Japan Airlines Co., Ltd. Feb 2012 Assistant to President and Senior Managing Executive Officer, Japan Airlines Co., Ltd. Dec 2015 Representative Director and Chairman, Kyocera Communication Systems Co., Ltd. Jun 2018 Outside Director, Konoike Transport Co., Ltd. (current) Sep 2019 Chairman, MTG Co., Ltd. Dec 2019 Chairman of the Board, MTG Co., Ltd. Dec 2021 Chairman of the Board, EVERING Co., Ltd. Mar 2025 Chairman of the Board, the Company (current)
1954-06-26
Gaichi TOYODA
Representative Director, President
Dec 1987 Joined the Company Jan 2006 President, Kobayashi Healthcare Europe, Ltd., International Sales Company Dec 2012 General Manager, Europe, Americas and China Strategy Department, International Business Division Mar 2015 General Manager, Europe and Americas Strategy Department, International Business Division Jul 2015 General Manager, Europe and Americas Strategy Department, International Business Division; President, Kobayashi Healthcare International, Inc. Mar 2023 Executive Officer, General Manager, International Business Division Jan 2025 Executive Officer, Head of International Business Headquarters Mar 2025 Representative Director, President (current)
1964-08-22
Yuji MATSUSHIMA
Director, Managing Executive Officer, Head of Research and Development Headquarters
Apr 2003 Joined Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.) Apr 2014 Seconded to Cabinet Secretariat, Health and Medical Strategy Office Oct 2017 Head of Advanced Chemistry Laboratory, Modality Research Laboratories, Research Division, Astellas Pharma Inc. Apr 2020 Joined the Company Jul 2020 General Manager, R&D Department, Central Research Laboratories Jan 2023 Director, Central Research Laboratories Mar 2023 Executive Officer, Director, Central Research Laboratories Jan 2025 Executive Officer, Head of Research and Development Headquarters Mar 2025 Director, Managing Executive Officer, Head of Research and Development Headquarters (current)
1975-07-12
Akihiro KOBAYASHI
Director, Executive Officer in charge of Compensation, Head of Compensation Response Headquarters
Mar 1998 Joined the Company Jun 2001 Executive Officer, President, Manufacturing Company Jun 2004 Director, President, International Sales Company; General Manager, Marketing Office Jun 2007 Managing Director Mar 2009 Senior Managing Director, Head of Product Business Headquarters Jun 2013 Representative Director, President Aug 2024 Director in charge of Compensation, Executive Officer Jan 2026 Director in charge of Compensation, Executive Officer, Head of Compensation Response Headquarters (current)
1971-05-13
Akio TAKAHASHI
Outside Director
Apr 1978 Joined Daiwa Securities Co., Ltd. Apr 2009 Senior Managing Director, Daiwa Securities SMBC Co., Ltd. (now Daiwa Securities Co., Ltd.) Jun 2012 Director and Executive Vice President, Daiwa Securities Group Inc. Apr 2015 Representative Director, President, Daiwa Investment Management Co., Ltd. Dec 2015 Outside Director, Green Thermal Co., Ltd. Mar 2016 Outside Director, Kantatsu Co., Ltd. Jul 2017 Outside Director, Biomass Fuel Co., Ltd. (current) Jun 2019 Outside Director, Suzumo Machinery Co., Ltd. (current) Dec 2019 Outside Director, MTG Co., Ltd. Mar 2025 Outside Director, the Company (current)
1956-03-15
Misa KUSUMOTO
Outside Director
Apr 1994 Joined P&G Far East, Inc. (now P&G Japan) Oct 1997 Senior Assistant Brand Manager, 'SK-II', P&G Far East, Inc. Oct 1999 New Brand Development Manager, Food and Beverage Category, P&G Far East, Inc. Oct 2001 Marketing consultant (current) Oct 2013 External Lecturer, Globis Management School (current) Feb 2022 Director, CMO, Selfactor Co., Ltd. (current) Feb 2024 Outside Director, North Sand Co., Ltd. (current) Mar 2025 Outside Director, the Company (current)
1972-02-16
Toshiaki KADOKAWA
Outside Director
Mar 1996 Completed doctoral program, Graduate School of Medicine, Keio University Jan 1999 Assistant, School of Medicine, Keio University Jul 1999 Research Fellow, Division of Nephrology, University of Washington Apr 2002 Assistant, Department of Nephrology, Endocrinology and Metabolism, School of Medicine, Keio University Apr 2007 Assistant Professor, Department of Nephrology, Endocrinology and Metabolism, School of Medicine, Keio University Jul 2014 Professor, Center for Medical Education, School of Medicine, Keio University (current) Jun 2020 Director, The Japanese Society of Nephrology Oct 2021 Vice Dean, School of Medicine, Keio University (current) Jul 2024 Director, Japan Society for Medical Education (current) Mar 2025 Outside Director, the Company (current)
1965-12-05
Masato MOURI
Outside Director, Audit and Supervisory Committee Member
Apr 1979 Joined International Telegraph and Telephone Corporation (now KDDI Corporation) Sep 2000 Joined Nihon Telecom Co., Ltd. (now SoftBank Corp.) Jul 2005 Joined Chuo Aoyama Audit Corporation Jun 2007 Joined Deloitte Touche Tohmatsu (now Deloitte Touche Tohmatsu LLC) Jul 2010 Director, Deloitte Touche Tohmatsu LLC Oct 2013 Representative Director, Crowe Horwath Global Risk Consulting Co., Ltd. Apr 2017 Professor, Department of Global Innovation Studies, Faculty of International Studies, Toyo University (current) Jun 2018 Outside Audit & Supervisory Board Member, Technos Japan Co., Ltd. Mar 2019 Outside Audit & Supervisory Board Member, Beltra Co., Ltd. Jun 2020 Outside Director, Audit and Supervisory Committee Member, Technos Japan Co., Ltd. Jun 2020 Outside Director, Audit and Supervisory Committee Member, Pado Inc. (now Def consulting Inc.) Mar 2023 Outside Director, Audit and Supervisory Committee Member, Beltra Co., Ltd. (current) Mar 2025 Outside Director, the Company (current) Jun 2025 Auditor, Ferris Jogakuin School Corporation (current) Sep 2025 Visiting Professor, Global Business Field, Akita International University (current) Mar 2026 Outside Director (Audit and Supervisory Committee Member), the Company
1956-01-28
Yoshio KATAE
Outside Director, Audit and Supervisory Committee Member
Apr 1981 Joined Komatsu Ltd. Jan 2003 General Manager, General Affairs Department, Osaka Plant, Production Division, Komatsu Ltd. Jul 2007 General Manager, General Affairs Department, Komatsu Ltd. Jul 2013 Executive Officer, Secretary Office Director, in charge of Crisis Management, Komatsu Ltd. Oct 2015 Executive Officer, Secretary Office Director, in charge of Crisis Management; Director, Komatsu Economic Strategy Research Institute, Komatsu Ltd. Apr 2017 Executive Officer, Secretary Office Director, in charge of General Affairs, Compliance and Crisis Management, Komatsu Ltd. Apr 2018 Managing Executive Officer, Komatsu Ltd. Jul 2019 Adviser, Komatsu Ltd. Mar 2022 Outside Director, the Company (current) Mar 2026 Outside Director (Audit and Supervisory Committee Member), the Company
1956-10-28
Shinsuke MATSUMOTO
Outside Director, Audit and Supervisory Committee Member
Apr 1997 Registered with Daiichi Tokyo Bar Association; joined Nishimura & Asahi Oct 1999 Joined Nagashima Ohno & Tsunematsu Sep 2002 Worked at Skadden, Arps, Slate, Meagher & Flom LLP, New York Office Mar 2003 Registered as attorney-at-law in New York State Apr 2004 Joined Nakamura & Tsunoda Law Offices Jan 2005 Partner, Nakamura, Tsunoda & Matsumoto Law Offices (current) Dec 2005 Registered with Tokyo Bar Association Mar 2017 Outside Audit & Supervisory Board Member, Be Trend Co., Ltd. (current) Jun 2023 Outside Audit & Supervisory Board Member, Soken Chemical & Engineering Co., Ltd. (current) Mar 2025 Outside Director, the Company (current) Nov 2025 Supervisory Executive Officer, Japan Hotel REIT Investment Corporation (current) Mar 2026 Outside Director (Audit and Supervisory Committee Member), the Company
1970-04-17
Large Shareholding Reports
Oasis Management Company Ltd.
2026-09-09
13.37%→14.41%
Oasis Management Company Ltd.
2026-05-13
13.06%→13.37%
Oasis Management Company Ltd.
2025-12-26
10.10%→13.06%
Oasis Management Company Ltd.
2024-12-25
7.54%→10.10%
Oasis Management Company Ltd.
2024-11-19
5.20%→7.54%
Oasis Management Company Ltd.
2024-10-23
5.20%
Oasis Management Company Ltd.
2024-07-24
5.20%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-09
Large Shareholding Report
EDINET
2026-08-07
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-06
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-05-13
Large Shareholding Report
TDnet
2026-05-08
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-25
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2025-12-26
Large Shareholding Report
TDnet
2025-11-11
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-09
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-12-25
Large Shareholding Report
EDINET
2024-11-19
Large Shareholding Report
EDINETAmended
2024-10-23
Change Report
EDINET
2024-08-09
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-07-24
Large Shareholding Report
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-28
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-30
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-03-30
Annual Securities Report
EDINET
2021-11-11
Quarterly Securities Report
EDINET
2021-08-06
Quarterly Securities Report
EDINET
2021-05-13
Quarterly Securities Report
EDINET
2021-03-26
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →